daratumumab + ixazomib + dexamethasone

The combination of daratumumab, ixazomib, and dexamethasone is used as a second-line therapy for patients with relapsed or refractory multiple myeloma, particularly those previously treated with lenalidomide-based regimens. Daratumumab is a monoclonal antibody that targets CD38 on myeloma cells, inducing cell death through direct cytotoxicity and immune-mediated mechanisms. Ixazomib is an oral small molecule proteasome inhibitor that disrupts protein degradation in cancer cells, leading to apoptosis. Dexamethasone is a synthetic glucocorticoid corticosteroid that exerts anti-inflammatory and immunosuppressive effects and enhances the efficacy of antimyeloma agents. This combination has demonstrated rapid responses and acceptable safety profiles in clinical studies for relapsed/refractory multiple myeloma[1][2][3][4][5].

Other names

Dara-Ixa-dex